Therefore, it would be intriguing to conduct in vitro experiments to assess the potential of the selected hit compounds for mitigating dysregulated expression of IL-1β, an underlying factor contributing to the severity of both COVID-19 and dry eye disease. This evidence concerns the gene IL1B and COVID-19.